ATE501121T1 - 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen - Google Patents

4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen

Info

Publication number
ATE501121T1
ATE501121T1 AT07728049T AT07728049T ATE501121T1 AT E501121 T1 ATE501121 T1 AT E501121T1 AT 07728049 T AT07728049 T AT 07728049T AT 07728049 T AT07728049 T AT 07728049T AT E501121 T1 ATE501121 T1 AT E501121T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
phenylmethylüpiperidine
methanesulfoate
fluorphenoxy
synthetic methods
Prior art date
Application number
AT07728049T
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Pestana Ramon Mosquera
Duran Ma Carmen Pumar
Avello Antonio Toledo
Mori Gonzalo Canal
Martoen Maravillas Bordell
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Application granted granted Critical
Publication of ATE501121T1 publication Critical patent/ATE501121T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07728049T 2006-05-12 2007-04-12 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen ATE501121T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380112A EP1854785A1 (de) 2006-05-12 2006-05-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulponat: Anwendungen, Verfahren zur Synthese und pharmazeutische Zusammensetzungen
US11/486,350 US20070265306A1 (en) 2006-05-12 2006-07-13 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
PCT/EP2007/053582 WO2007131846A1 (en) 2006-05-12 2007-04-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE501121T1 true ATE501121T1 (de) 2011-03-15

Family

ID=37061190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07728049T ATE501121T1 (de) 2006-05-12 2007-04-12 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen

Country Status (23)

Country Link
US (2) US20070265306A1 (de)
EP (2) EP1854785A1 (de)
JP (1) JP2009536962A (de)
KR (1) KR20090009971A (de)
CN (1) CN101443312B (de)
AT (1) ATE501121T1 (de)
AU (1) AU2007251663B2 (de)
BR (1) BRPI0710856A2 (de)
CA (1) CA2651933A1 (de)
CY (1) CY1111460T1 (de)
DE (1) DE602007013040D1 (de)
DK (1) DK2032534T3 (de)
ES (1) ES2362683T3 (de)
HR (1) HRP20110333T1 (de)
MX (1) MX2008014439A (de)
MY (1) MY148406A (de)
NO (1) NO20085052L (de)
NZ (1) NZ572714A (de)
PL (1) PL2032534T3 (de)
RS (1) RS51858B (de)
RU (1) RU2412169C2 (de)
SI (1) SI2032534T1 (de)
WO (1) WO2007131846A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854785A1 (de) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulponat: Anwendungen, Verfahren zur Synthese und pharmazeutische Zusammensetzungen
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
US7994209B2 (en) * 2009-07-13 2011-08-09 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
JP5714580B2 (ja) 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 3−フェノキシメチルピロリジン化合物
ES2533434T3 (es) 2010-10-11 2015-04-10 Theravance Biopharma R&D Ip, Llc Inhibidores de la captación de la serotonina
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
US9002322B2 (en) * 2011-09-29 2015-04-07 Apple Inc. Authentication with secondary approver
CN104887675B (zh) * 2014-03-05 2018-08-07 江苏恩华药业股份有限公司 [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
EP1854785A1 (de) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulponat: Anwendungen, Verfahren zur Synthese und pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
WO2007131846A1 (en) 2007-11-22
RS51858B (sr) 2012-02-29
SI2032534T1 (sl) 2011-06-30
EP2032534B1 (de) 2011-03-09
RU2412169C2 (ru) 2011-02-20
DE602007013040D1 (de) 2011-04-21
CN101443312A (zh) 2009-05-27
JP2009536962A (ja) 2009-10-22
MY148406A (en) 2013-04-30
KR20090009971A (ko) 2009-01-23
AU2007251663B2 (en) 2012-04-05
ES2362683T3 (es) 2011-07-11
HK1130053A1 (en) 2009-12-18
AU2007251663A1 (en) 2007-11-22
US20070265306A1 (en) 2007-11-15
NO20085052L (no) 2008-12-04
CN101443312B (zh) 2011-07-06
RU2008148941A (ru) 2010-06-20
CY1111460T1 (el) 2015-08-05
US20100004283A1 (en) 2010-01-07
CA2651933A1 (en) 2007-11-22
DK2032534T3 (da) 2011-04-26
EP2032534A1 (de) 2009-03-11
EP1854785A1 (de) 2007-11-14
PL2032534T3 (pl) 2011-08-31
BRPI0710856A2 (pt) 2011-05-17
MX2008014439A (es) 2009-01-21
HRP20110333T1 (hr) 2011-06-30
NZ572714A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
ATE501121T1 (de) 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
EA201270505A1 (ru) Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение
ATE517882T1 (de) Chinolinderivate
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
NO20090328L (no) Nye forbindelser 385
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
DK2150530T3 (da) Substituerede sulfonamid-derivater
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ATE442846T1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
EA200970398A1 (ru) Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
BRPI0411603A (pt) 4-(aminometil)-piperidina benzamidas como antagonistas 5ht4
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2032534

Country of ref document: EP